<DOC>
	<DOC>NCT01342744</DOC>
	<brief_summary>The purpose of this study is to determine the effects of metformin on cardiovascular risk factors in postmenopausal women with metabolic syndrome.</brief_summary>
	<brief_title>Metformin in Postmenopausal Women With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Postmenopausal women aged 4560 years with metabolic syndrome according to The American Heart Association and The National Heart, Lung, and Blood Institute Previous cardiovascular diseases Contraindicated to metformin: serum creatinine &gt;1.4 mg/dL, liver disease, alcoholism, congestive heart failure, chronic hypoxic lung disease, prior history of lactic acidosis Previous administration of metformin, other hypoglycemic drugs, lipidlowering drugs, sex steroids, antiplatelet drugs within 3 months before enrollment Fasting blood sugar ≥ 200 mg/dL or HbA1c &gt;8% Serum triglyceride ≥500 mg/dL Abnormal EKG</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cardiovascular risk factors</keyword>
</DOC>